

Patient ID SA00151722	Patient Name TESTING, KRASW	Birth Date 1977-02-01	Sex F	Age 45
Order Number SA00151722	Client Order Number SA00151722	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 25 Mar 2022 07:30		

KRAS Mutation Analysis, Peritoneal

Result Summary

MCR

POSITIVE

Result

MCR

KRAS status: Mutant

Interpretation

MCR

The results of this assay should be interpreted in the context of other clinicopathologic findings. In the context of molecular peritoneal staging of pancreatic ductal adenocarcinoma during staging laparoscopy with peritoneal washings and cytology, the presence of detectable peritoneal fluid mutant cfKRAS (positive test) has been associated with clinically positive laparoscopic findings (gross metastases and/or positive peritoneal cytology) and elevated peritoneal fluid CA19-9 and/or CEA, and may portend an increased risk of residual/recurrent pancreatic cancer metastases within the peritoneal cavity. However, a positive result does not entirely rule in peritoneal dissemination.

REFERENCES

1. J Am Coll Surg. 2021 Jul;233(1):73-80 (PMID 34022414)

Specimen

MCR

Peritoneal

Method

MCR

Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. Tumor DNA was isolated and evaluated for the presence of KRAS codons 12, 13, 61, and 146 mutations using digital droplet PCR analysis.

Disclaimer

1 MCR

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Rare polymorphisms exist that could lead to false-negative or false-positive results.

This assay was designed to detect KRAS codon 12, 13, 61, and 146 mutations.

A negative result does not rule out the presence of a mutation that may be present but below the limit of detection for this assay (approximately 0.1-0.5%).

Released By

MCR

Benjamin R. Kipp, Ph.D.

Received: 25 Mar 2022 09:35

Reported: 25 Mar 2022 13:58

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292